This document has not been cited yet.

1. Adams, C. P., & Brantner, V. V. (2006). Estimating the cost of new drug development: Is it really $802 million? Health Affairs, 25(2), 420–428.
   Paper not yet in RePEc: Add citation now
   
2. Agrawal, A. (2006). Engaging the inventor: Exploring licensing strategies for university inventions and the role of latent knowledge. Strategic Management Journal, 27(1), 63–79.
   Paper not yet in RePEc: Add citation now
   

3. Anckaert, P., Cassiman, D., & Cassiman, B. (2020). Fostering practice-oriented and use-inspired science in biomedical research. Research Policy, 49(2), 103900.

4. Arora, A., & Gambardella, A. (1994). Evaluating technological information and utilizing it: Scientific knowledge, technological capability, and external linkages in biotechnology. Journal of Economic Behavior & Organization, 24, 91–114.

5. Arora, A., Belenzon, S., & Patacconi, A. (2018). The decline of science in corporate R&D. Strategic Management Journal, 39, 3–32.
   Paper not yet in RePEc: Add citation now
   

6. Arora, A., Belenzon, S., & Sheer, L. (2021). Knowledge spillovers and corporate investment in scientific research. American Economic Review, 111(3), 871–898.

7. Arora, A., Belenzon, S., Patacconi, A., & Suh, J. (2020). The changing structure of American Innovation: Some cautionary remarks for economic growth. Innovation Policy and the Economy, National Bureau of Economic Research, 20, 39–93.

8. Arora, A., Fosfuri, A., & Gambardella, A. (2001). Markets for technology: The economics of innovation and corporate strategy. MIT Press.
   Paper not yet in RePEc: Add citation now
   

9. Arora, A., Gambardella, A., Magazinni, L., & Pammoli, F. (2009). A breath of fresh air? Firm type, scale, scope, and selection effects in drug development. Management Science, 55(10), 1638–1653.

10. Barrenho, E., Miraldo, M. and Smith, P. C. (2013) “The determinants of attrition in drug development: A duration analysis.” Working papers 12204, Imperial College, London.

11. Baycan, T., & Stough, R. R. (2013). Bridging knowledge to commercialization: The good, the bad, and the challenging. Annals of Regional Science, 50, 367–405.

12. Belderbos, R., Cassiman, B., Faems, D., Leten, B., & Van Looy, B. (2014). Exploring the value appropriation and value creation implications of co-patenting with different partners. Research Policy, 43(5), 841–852.
    Paper not yet in RePEc: Add citation now
    
13. Belderbos, R., Gilsing, V. A., & Suzuki, S. (2016). Direct and mediated ties to universities: “Scientific absorptive capacity and innovation performance of pharmaceutical firms. Strategic Organization, 14(1), 32–52.
    Paper not yet in RePEc: Add citation now
    
14. Belderbos, R., Leten, B., & Suzuki, S. (2017). Scientific research, firm heterogeneity, and foreign R&D locations of multinational firms. Journal of Economics & Management Strategy, 26(3), 691–711.
    Paper not yet in RePEc: Add citation now
    

15. Belenzon, S., & Schankerman, M. (2013). Spreading the word: Geography, policy, and knowledge spillovers. Review of Economics and Statistics, 95(3), 884–903.

16. Bhogal, N., & Balls, M. (2008). Translation of new technologies: From basic research to drug discovery and development. Current Drug Discovery Technologies, 5(3), 250–262.
    Paper not yet in RePEc: Add citation now
    

17. Blind, K., Edler, R., Frietsch, R., & Smoch, U. (2006). Motives to patent: Empirical evidence from Germany. Research Policy, 35, 655–672.

18. Calderini, M., Franzoni, C., & Vezzulli, A. (2007). If star scientists do not patent: The effect of productivity, basicness and impact on the decision to patent in the academic world. Research Policy, 36(3), 303–319.

19. Callaert, J., Pellens, M., & Van Looy, B. (2013). Sources of inspiration? Making sense of scientific references in patents. Scientometrics, 98(3), 1617–1629.
    Paper not yet in RePEc: Add citation now
    
20. Campbell, J. J. (2005) Understanding Pharma: A primer on how pharmaceutical companies really work. Raleigh: Pharmaceutical Institute.
    Paper not yet in RePEc: Add citation now
    
21. Ceccagnoli, M., & Jiang, L. I. N. (2013). The cost of integrating external technologies: Supply and demand drivers of value creation in the markets for technology. Strategic Management Journal, 34(4), 404–425.
    Paper not yet in RePEc: Add citation now
    
22. Chesbrough, H., & Chen, E. L. (2013). Recovering abandoned compounds through expanded external IP licensing. California Management Review, 55(4), 83–101.
    Paper not yet in RePEc: Add citation now
    

23. Chiou, J.-Y., et al. (2016). Learning from successes and failures in pharmaceutical R&D. Journal of Evolutionary Economics, 26, 271–290.

24. Cockburn, I. M. (2006). Is the pharmaceutical industry in a productivity crisis? Innovation Policy and the Economy, 7, 1–32.
    Paper not yet in RePEc: Add citation now
    

25. Cockburn, I. M., & Henderson, R. M. (1998). Absorptive capacity, coauthoring behavior, and the organization of research in drug discovery. Journal of Industrial Economics, 46(2), 157–182.

26. Cockburn, l. M. and Henderson, R. M. (2001). Publicly funded science and the productivity of the pharmaceutical industry. Innovation Policy and the Economy, 1, 1–34.

27. Cohen, W., & Levinthal, D. (1989). Innovation and learning: The two faces of R&D. Economic Journal, 99, 569–596.

28. Colen, L., Belderbos, R., Kelchtermans, S., & Leten, B. (2022). Reaching for the stars: When does basic research collaboration between firms and academic star scientists benefit firm invention performance? Journal of Product Innovation Management, 39(2), 222–264.
    Paper not yet in RePEc: Add citation now
    
29. Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014). Lessons learned from the fate of AstraZeneca’s drug pipeline: A five-dimensional framework. Nature Reviews Drug Discovery, 13(6), 419–431.
    Paper not yet in RePEc: Add citation now
    
30. Cormier, Z. (2019). Six drugs discovered by accident. Science Focus. https://www.sciencefocus.com/science/six-drugs-discovered-by-accident/ .
    Paper not yet in RePEc: Add citation now
    

31. Crispeels, T., Willems, J., & Scheerlinck, I. (2018). Public–private collaborations in drug development: Boosting innovation or alleviating risk? Public Management Review, 20(2), 273–292.

32. Czarnitzki, D., Hussinger, K., & Leten, B. (2020). How valuable are patent blocking strategies? Review of Industrial Organization, 56(3), 409–434.

33. De Wit-de Vries, E., Dolfsma, W. A., van der Windt, H. J., & Gerkema, M. P. (2019). Knowledge transfer in university-industry research partnerships: A review. Journal of Technology Transfer, 44, 1236–1255.

34. Della Malva, A., Leten, B., Kelchtermans, S., & Veugelers, R. (2015). Basic science as a prescription for technological breakthroughs in the pharmaceutical industry. Journal of Technology Transfer, 40, 670–695.
    Paper not yet in RePEc: Add citation now
    
35. Dimasi, J. A. (2015) “Innovation in the pharmaceutical industry : Trends in time , risks , and costs.”.
    Paper not yet in RePEc: Add citation now
    

36. DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22(2), 151–185.

37. Ding, M., Dong, S., Eliashberg, J., & Gopalakrishnan, A. (2014). Portfolio management in new drug development. In M. Ding, J. Eliashberg, & S. Stremersch (Eds.), Innovation and marketing in the pharmaceutical industry: Emerging practices, research, and policies (pp. 83–118). Springer.
    Paper not yet in RePEc: Add citation now
    
38. Dobson, P. D., & Kell, D. B. (2008). “Carrier-mediated cellular uptake of pharmaceutical drugs: An exception or the rule?”Nature reviews drug discovery. Nature Publishing Group, 7(3), 205–220.
    Paper not yet in RePEc: Add citation now
    
39. Drahl, C. (2014). How does acetaminophen work? Researchers Still Aren’t Sure. A clearer picture might pave the way for new painkillers. Chemical & Engineering News, Vol. 92 (29).
    Paper not yet in RePEc: Add citation now
    
40. Eichler, H.-G., et al. (2009). “Safe drugs and the cost of good intentions”, new England journal of medicine. Massachusetts Medical Society, 360(14), 1378–1380.
    Paper not yet in RePEc: Add citation now
    
41. Eliëns, R., Eling, K., Gelper, S., & Langerak, F. (2018). Rational versus intuitive gatekeeping: Escalation of commitment in the front end of NPD. Journal of Product Innovation Management, 35(6), 890–907.
    Paper not yet in RePEc: Add citation now
    

42. Fabrizio, K. R. (2009). Absorptive capacity and the search for innovation. Research Policy, 38(2), 255–267.

43. Fleming, L., & Sorenson, O. (2004). Science as a map in technological search. Strategic Management Journal, 25(89), 909–928.

44. Franzoni, C., Stephan, P. and Veugelers, R. (2021). Funding risky research, NBER working paper No. 28905, National Bureau of Economic Research.
    Paper not yet in RePEc: Add citation now
    
45. Gambardella, A. (1992). Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Research Policy, 21(5), 391–407.
    Paper not yet in RePEc: Add citation now
    

46. Gittelman, M., & Kogut, B. (2003). Does good science lead to valuable knowledge? Biotechnology firms and the evolutionary logic of citation patterns. Management Science, 49(4), 366–382.

47. Griliches, Z. (1986) Productivity, R&D, and basic research at the firm level in the 1970s, American Economic Review, March, 141–154.
    Paper not yet in RePEc: Add citation now
    

48. Hart, O., & Moore, J. (1990). Property rights and the nature of the firm. Journal of Political Economy, 98(6), 1119–1158.

49. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology, 32(1), 40–51.
    Paper not yet in RePEc: Add citation now
    
50. Hilkenmeier, F., Fechtelpeter, C., & Decius, J. (2021). How to foster innovation in SMEs: Evidence of the effectiveness of a project-based technology transfer approach. Journal of Technology Transfer, Published Online,. https://doi.org/10.1007/s10961-021-09913-x .
    Paper not yet in RePEc: Add citation now
    
51. Jones, C. I. (1995). R&D-based models of economic growth. Journal of Political Economy, 103(4), 759–784.
    Paper not yet in RePEc: Add citation now
    

52. Klueter, T., Monteiro, L. F., & Dunlap, D. R. (2017). Standard vs. partnership-embedded licensing: Attention and the relationship between licensing and product innovations. Research Policy, 46(9), 1629–1643.

53. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews: Drug Discovery, 3(August), 1–5.
    Paper not yet in RePEc: Add citation now
    
54. LaMattina, J. L. (2011). The impact of mergers on pharmaceutical R&D. Nature Reviews Drug Discovery, 10, 559–560.
    Paper not yet in RePEc: Add citation now
    

55. Laursen, K., Leone, M. I., & Torrisi, S. (2010). Technological exploration through licensing: New insights from the licensee’s point of view. Industrial and Corporate Change, 19(3), 871–897.

56. Lendrem, D., Stephen, J. S., Lendrem, B. C., & Isaacs, J. (2015). R&D productivity rides again? Pharmaceutical Statistics, 14(1), 1–3.
    Paper not yet in RePEc: Add citation now
    

57. Leone, M. I., & Reichstein, T. (2012). Licensing-in fosters rapid invention! The effect of the grant-back clause and technological unfamiliarity. Strategic Management Journal, 33(8), 965–985.

58. Leten, B., Kelchtermans, S., & Belderbos, R. (2022). How does basic research improve innovation performance in the world’s major pharmaceutical firms? Industry & Innovation, 29(3), 396–424.
    Paper not yet in RePEc: Add citation now
    

59. Lim, K. (2004). The relationship between research and innovation in the semiconductor and pharmaceutical industries (1981–1997). Research Policy, 33(2), 287–321.

60. Mak, I. W., Evaniew, N., & Ghert, M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research, 6(2), 114.
    Paper not yet in RePEc: Add citation now
    
61. Malik, T. (2011). Vertical alliance and vertical integration for the inflow of technology and new product development in the pharmaceutical industry. Technology Analysis & Strategic Management. Routledge, 23(8), 851–864. https://doi.org/10.1080/09537325.2011.604154 .
    Paper not yet in RePEc: Add citation now
    
62. McGonigle, P., & Ruggeri, B. (2014). Animal models of human disease: Challenges in enabling translation. Biochemical Pharmacology, 87(1), 162–171.
    Paper not yet in RePEc: Add citation now
    

63. Meyer, M. (2000). Does science push technology? Patents citing scientific literature. Research Policy, 29, 409–434.

64. Morgan, P., et al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discovery Today. Elsevier Current Trends, 17(9–10), 419–424.
    Paper not yet in RePEc: Add citation now
    
65. Mullard, A. (2016). Parsing clinical success rates. Nature Reviews Drug Discovery, 15(7), 447.
    Paper not yet in RePEc: Add citation now
    
66. Natalicchio, A., Messeni Petruzzelli, A., & Garavelli, A. C. (2014). A literature review on markets for ideas: Emerging characteristics and unanswered questions. Technovation. Elsevier, 34(2), 65–76.
    Paper not yet in RePEc: Add citation now
    
67. Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). “The productivity crisis in pharmaceutical R&D”, nature reviews drug discovery. Nature Publishing Group, 10(6), 428–438.
    Paper not yet in RePEc: Add citation now
    
68. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). “How to improve R&D productivity: The pharmaceutical industry’s grand challenge”, nature reviews drug discovery. Nature Publishing Group, 9(3), 203–214.
    Paper not yet in RePEc: Add citation now
    

69. Pavitt, K. (1991). What makes basic research economically useful? Research Policy., 20(2), 109–119.

70. Peck, R. W., Lendrem, D. W., Lendrem, B. C., & Isaacs, J. D. (2015). Why is it hard to terminate failing projects in pharmaceutical R&D? Nature Publishing Group, 14, 663–664.
    Paper not yet in RePEc: Add citation now
    
71. Pharmacy times (2016). 5 Surprising stories of accidental drug discoveries. Pharmacy Times. https://www.pharmacytimes.com/view/5-surprising-stories-of-accidental-drug-discoveries .
    Paper not yet in RePEc: Add citation now
    
72. Pisano, G. (1997). The development factory. Harvard Business School Press.
    Paper not yet in RePEc: Add citation now
    
73. PPD (2017) About drug discovery and development. Available at: http://www.ppdi.com/About/About-Drug-Discovery-and-Development .
    Paper not yet in RePEc: Add citation now
    
74. Qian, T., Zhu, S., & Hoshida, Y. (2019). Use of big data in drug development for precision medicine: An update. Expert Review of Precision Medicine and Drug Development, 4(3), 189–200. https://doi.org/10.1080/23808993.2019.1617632 .
    Paper not yet in RePEc: Add citation now
    

75. Rosenberg, N. (1990). Why do firms do basic research (with their own money)? Research Policy, 19(2), 165–174.

76. Rosenkopf, L., & Nerkar, A. (2001). Beyond local search: Boundary-spanning, exploration, and impact in the optical disk industry. Strategic Management Journal, 22, 287–306.

77. Sams-Dodd, F. (2013). Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discovery Today, 18, 211–217.
    Paper not yet in RePEc: Add citation now
    
78. Schuhmacher, A., Hinder, M., & Gassmann, O. (2016). Value creation in the pharmaceutical industry: The critical path to innovation. John Wiley.
    Paper not yet in RePEc: Add citation now
    

79. Teece, D. J. (1988). Capturing value from technological innovation: Integration, strategic partnering, and licensing decisions. Interfaces, 18(3), 46–61.

80. Thomas, D. W., Burns, J., Audette, J., Carroll, A., Dow-Hygelund, C., & Hay, M. (2016). Clinical development success rates 2006–2015. BIO Industry Analysis, 1(16), 25.
    Paper not yet in RePEc: Add citation now
    
81. Thumm, N. (2004). Strategic patenting in biotechnology. Technology Analysis & Strategic Management, 16(4), 529–538.
    Paper not yet in RePEc: Add citation now
    

82. Thursby, J. G., & Thursby, M. C. (2011). Faculty participation in licensing: Implications for research. Research Policy, 40(1), 20–29.

83. Tijssen, R. (2001). Global and domestic utilization of industrial relevant science: Patent citation analysis of science-technology interactions and knowledge flows. Research Policy, 30, 35–54.
    Paper not yet in RePEc: Add citation now
    

84. Von Hippel, E. (1994). “Sticky information” and the locus of problem solving: Implications for innovation. Management Science, 40(4), 429–439.

85. Workman, P. (2015) Why ‘basic research’ is critical for understanding and treating cancer., The Institute of Cancer Research (ICR), UK.
    Paper not yet in RePEc: Add citation now
    
86. Zucker, L. G., & Darby, M. R. (1996). Star scientists and institutional transformation: Patterns of invention and innovation in the formation of the biotechnology industry. Proceedings of the National Academy of Sciences of the United States of America, 93(23), 12709–12716.
    Paper not yet in RePEc: Add citation now
    

87. Zucker, L. G., Darby, M. R., & Armstrong, J. (2002). Commercializing knowledge: University science, knowledge capture, and firm performance in biotechnology. Management Science, 48(1), 138–153.

1. When the drugs (don’t) work: The role of science in product commercialization. (2025). Anckaert, Paul-Emmanuel.
   In: Research Policy.
   RePEc:eee:respol:v:54:y:2025:i:5:s0048733325000666.

   Full description at Econpapers || Download paper

2. Many are called, few are chosen: the role of science in drug development decisions. (2024). Belderbos, Rene ; Kelchtermans, Stijn ; Colen, Linde ; Leten, Bart.
   In: The Journal of Technology Transfer.
   RePEc:kap:jtecht:v:49:y:2024:i:2:d:10.1007_s10961-022-09982-6.

   Full description at Econpapers || Download paper

3. Science and technology evaluation reform and universities’ innovation performance. (2024). Li, Shihan ; Shen, QI ; Jiang, Chun.
   In: Technology in Society.
   RePEc:eee:teinso:v:78:y:2024:i:c:s0160791x24001623.

   Full description at Econpapers || Download paper

4. The Industrialisation of Sustainable Construction: A Transdisciplinary Approach to the Large-Scale Introduction of Compacted Mineral Mixtures (CMMs) into Building Construction. (2023). Cudmani, Roberto ; Off, Rebecca ; Hollenbach, Pia ; Fritz, Oliver ; Buhler, Michael Max ; Baltes, Guido ; Kortmann, Geraldine ; Birle, Emanuel ; Lang, Christina ; Schmidt, Wolfram ; Michalski, Alexander ; Meyer, Sonja.
   In: Sustainability.
   RePEc:gam:jsusta:v:15:y:2023:i:13:p:10677-:d:1188334.

   Full description at Econpapers || Download paper

5. Nobel laurates and the role of the industry in the emergence of new scientific breakthroughs. (2022). Weil, Benoit ; Plantec, Quentin ; le Masson, Pascal.
   In: Post-Print.
   RePEc:hal:journl:hal-03727378.

   Full description at Econpapers || Download paper

6. Exploring network dynamics in science: the formation of ties to knowledge translators in clinical research. (2021). Rake, Bastian ; Deste, Pablo ; McKelvey, Maureen.
   In: Journal of Evolutionary Economics.
   RePEc:spr:joevec:v:31:y:2021:i:5:d:10.1007_s00191-020-00716-1.

   Full description at Econpapers || Download paper

7. Firm Knowledge, Neighborhood Diversity and Innovation. (2014). Wixe, Sofia.
   In: Working Paper Series in Economics and Institutions of Innovation.
   RePEc:hhs:cesisp:0360.

   Full description at Econpapers || Download paper

8. Inter-firm R&D networks in pharmaceutical biotechnology: What determines firms centrality-based partnering capability. (2013). Riedel, Nadine ; Krogmann, Yin ; Schwalbe, Ulrich.
   In: FZID Discussion Papers.
   RePEc:zbw:fziddp:752013.

   Full description at Econpapers || Download paper

9. The Rise and Fall of R&D Networks. (2013). Schweitzer, Frank ; Napoletano, Mauro ; Tomasello, Mario V ; Garas, Antonios.
   In: Sciences Po publications.
   RePEc:spo:wpmain:info:hdl:2441/f6h8764enu2lskk9p5487a6cm.

   Full description at Econpapers || Download paper

10. The Rise and Fall of R&D Networks. (2013). Napoletano, Mauro ; Tomasello, Mario V ; Garas, Antonios.
    In: Sciences Po Economics Discussion Papers.
    RePEc:spo:wpecon:info:hdl:2441/f6h8764enu2lskk9p5487a6cm.

    Full description at Econpapers || Download paper

11. Patent Trading Flows of Small and Large Firms. (2013). Serrano, Carlos ; Figueroa, Nicolas.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:18982.

    Full description at Econpapers || Download paper

12. Towards an open R&D system: Internal R&D investment, external knowledge acquisition and innovative performance. (2013). Berchicci, Luca.
    In: Research Policy.
    RePEc:eee:respol:v:42:y:2013:i:1:p:117-127.

    Full description at Econpapers || Download paper

13. An empirical analysis of technology absorption capacity of the Brazilian industry. (2013). Giglio, Ricardo ; Bittencourt, Pablo Felipe.
    In: Revista CEPAL.
    RePEc:ecr:col070:37011.

    Full description at Econpapers || Download paper

14. The effect of institutional ties on knowledge acquisition in uncertain environments. (2012). Gao, Shanxing ; Huang, Kuo-Feng ; Xu, Kai.
    In: Asia Pacific Journal of Management.
    RePEc:kap:asiapa:v:29:y:2012:i:2:p:387-408.

    Full description at Econpapers || Download paper

15. Is there complementarity or substitutability between internal and external R&D strategies?. (2012). Wang, Ning ; Hagedoorn, John.
    In: Research Policy.
    RePEc:eee:respol:v:41:y:2012:i:6:p:1072-1083.

    Full description at Econpapers || Download paper

16. Effective incomplete contracts and milestones in market-distant R&D collaboration. (2012). Scholderer, Joachim ; Kloyer, Martin.
    In: Research Policy.
    RePEc:eee:respol:v:41:y:2012:i:2:p:346-357.

    Full description at Econpapers || Download paper

17. Strategic alliances and product development in high technology new firms: The moderating effect of technological capabilities. (2012). Häussler, Carolin ; Zahra, Shaker A. ; Patzelt, Holger ; Haeussler, Carolin.
    In: Journal of Business Venturing.
    RePEc:eee:jbvent:v:27:y:2012:i:2:p:217-233.

    Full description at Econpapers || Download paper

18. Disparate association between alliance social capital and the global pharmaceutical firms performance. (2012). Malik, Tariq .
    In: International Business Review.
    RePEc:eee:iburev:v:21:y:2012:i:6:p:1017-1028.

    Full description at Econpapers || Download paper

19. Impact of Co-operation and Competences on the Innovating Behavior: A Micro-econometric Study of the French Firms. (2012). Karim, Kefi Mohamed .
    In: International Journal of Economics and Financial Issues.
    RePEc:eco:journ1:2012-04-15.

    Full description at Econpapers || Download paper

20. Determinants of innovation in a small open economy: A multidimensional perspective. (2012). Carvalho, Luísa ; Caiado, Jorge ; Costa, Teresa.
    In: CEMAPRE Working Papers.
    RePEc:cma:wpaper:1201.

    Full description at Econpapers || Download paper

21. To Make or to Buy: Is this the Question?. (2012). Pascucci, Stefano ; Bijman, Jos ; Royer, Annie.
    In: International Food and Agribusiness Management Review.
    RePEc:ags:ifaamr:132792.

    Full description at Econpapers || Download paper

22. Understanding the heterogeneity of cooperation on innovation: Firm-level evidence from Europe. (2011). Srholec, Martin.
    In: Working Papers on Innovation Studies.
    RePEc:tik:inowpp:20111201.

    Full description at Econpapers || Download paper

23. Recombinant knowledge and the evolution of innovation networks. (2011). Schweitzer, Frank ; Napoletano, Mauro ; König, Michael ; battiston, stefano ; Konig, Michael D..
    In: Journal of Economic Behavior & Organization.
    RePEc:eee:jeborg:v:79:y:2011:i:3:p:145-164.

    Full description at Econpapers || Download paper

24. Should I Make or Should I Buy? Innovation Strategies and Governance Structures in the Italian Food Sector. (2011). Pascucci, Stefano ; Bijman, Jos ; Royer, Annie.
    In: International Journal on Food System Dynamics.
    RePEc:ags:ijofsd:121856.

    Full description at Econpapers || Download paper

25. Contextual Effects on the Complementarities Between R&D Activities: An Empirical Analysis of the Korean Manufacturing Industry. (2009). Kim, Yeonbae ; Lee, Sungki ; Choi, Dong Hyuk.
    In: TEMEP Discussion Papers.
    RePEc:snv:dp2009:200917.

    Full description at Econpapers || Download paper

26. Drivers of the Offshore Outsourcing of R&D: Empirical Evidence from French Manufacturers. (2009). Zuniga, Pluvia ; Jabbour, Liza.
    In: Discussion Papers.
    RePEc:not:notgep:09/04.

    Full description at Econpapers || Download paper

27. Absorptive capacity and R&D tax policy: Are in-house and external contract R&D substitutes or complements?. (2009). Watkins, Todd ; Paff, Lolita.
    In: Small Business Economics.
    RePEc:kap:sbusec:v:33:y:2009:i:2:p:207-227.

    Full description at Econpapers || Download paper

28. Innovation success of non-R&D-performers: substituting technology by management in SMEs. (2009). Rammer, Christian ; Czarnitzki, Dirk ; Spielkamp, Alfred .
    In: Small Business Economics.
    RePEc:kap:sbusec:v:33:y:2009:i:1:p:35-58.

    Full description at Econpapers || Download paper

29. Managing external knowledge flows: The moderating role of absorptive capacity. (2009). Tribó, Josep ; Escribano, Alvaro ; Tribo, Josep A. ; Fosfuri, Andrea.
    In: Research Policy.
    RePEc:eee:respol:v:38:y:2009:i:1:p:96-105.

    Full description at Econpapers || Download paper

30. The Impact of M&A on Technology Sourcing Strategies. (2008). Cefis, Elena.
    In: LEM Papers Series.
    RePEc:ssa:lemwps:2008/25.

    Full description at Econpapers || Download paper

31. Complementarities of innovation activities: An empirical analysis of the German manufacturing sector. (2008). Schmiedeberg, Claudia.
    In: Research Policy.
    RePEc:eee:respol:v:37:y:2008:i:9:p:1492-1503.

    Full description at Econpapers || Download paper

32. Trade-related influences, foreign intellectual property rights and outbound international patenting. (2008). Kuo, Nai-Fong ; Yang, Chih-Hai.
    In: Research Policy.
    RePEc:eee:respol:v:37:y:2008:i:3:p:446-459.

    Full description at Econpapers || Download paper

33. Exploring the antecedents of potential absorptive capacity and its impact on innovation performance. (2008). Tribó, Josep ; Tribo, Josep A. ; Fosfuri, Andrea.
    In: Omega.
    RePEc:eee:jomega:v:36:y:2008:i:2:p:173-187.

    Full description at Econpapers || Download paper

34. The Effect of Venture Capital on Innovation Strategies. (2007). Penas, María ; Da Rin, Marco.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:13636.

    Full description at Econpapers || Download paper

35. Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry. (2007). Baden-Fuller, Charles ; Mangematin, Vincent ; Zhang, Jing.
    In: Post-Print.
    RePEc:hal:journl:hal-00424512.

    Full description at Econpapers || Download paper

36. Business R&D, Innovation and Economic Growth: An Evidence-Based Synthesis of the Policy Issues. (2006). Davis, Nick.
    In: Occasional Papers.
    RePEc:ris:nzmedo:2006_008.

    Full description at Econpapers || Download paper

37. R&D and Patenting Activity and the Propensity to Acquire in High Technology Industries. (2005). Hughes, Alan ; Desyllas, Panos.
    In: Industrial Organization.
    RePEc:wpa:wuwpio:0507008.

    Full description at Econpapers || Download paper

38. R&D boundaries of the firm: An estimation of the double-hurdle model on commissioned R&D, joint R&D, and licensing in Japan. (2005). Nakamura, Kenta ; Odagiri, Hiroyuki.
    In: Economics of Innovation and New Technology.
    RePEc:taf:ecinnt:v:14:y:2005:i:7:p:583-615.

    Full description at Econpapers || Download paper

39. R&D and Patenting Activity and the Propensity to Acquire in High Technology Industries. (2005). Hughes, Alan ; Dessyllas, Panayotis.
    In: Working Papers.
    RePEc:cbr:cbrwps:wp298.

    Full description at Econpapers || Download paper

40. Firm Assets and Investments in Open Source Software Products. (2005). Giarratana, Marco ; Fosfuri, Andrea ; Luzzi, Alessandra.
    In: DRUID Working Papers.
    RePEc:aal:abbswp:05-10.

    Full description at Econpapers || Download paper

41. Interaction between public research organizations and industry in biotechnology. (2003). Dalpe, Robert ; Nakamura, Masao.
    In: Managerial and Decision Economics.
    RePEc:wly:mgtdec:v:24:y:2003:i:2-3:p:171-185.

    Full description at Econpapers || Download paper

42. Evaluation of the Role of Universities in the Innovation Process. (2003). Becker, Wolfgang.
    In: Discussion Paper Series.
    RePEc:aug:augsbe:0241.

    Full description at Econpapers || Download paper

43. Innovation as co-evolution of scientific and technological networks: exploring tissue engineering. (2002). Murray, Fiona.
    In: Research Policy.
    RePEc:eee:respol:v:31:y:2002:i:8-9:p:1389-1403.

    Full description at Econpapers || Download paper

44. Technology as a major driver of health care costs: a cointegration analysis of the Newhouse conjecture. (2002). Okunade, Albert ; Murthy, Vasudeva N. R., .
    In: Journal of Health Economics.
    RePEc:eee:jhecon:v:21:y:2002:i:1:p:147-159.

    Full description at Econpapers || Download paper

45. Complementarity in the innovation strategy: Internal R&D, external technology acquisition, and cooperation in R&D.. (2002). veugelers, reinhilde ; Cassiman, Bruno.
    In: IESE Research Papers.
    RePEc:ebg:iesewp:d-0457.

    Full description at Econpapers || Download paper

46. Complementarity in the Innovation Strategy: Internal R&D, External Technology Acquisition and Cooperation. (2002). veugelers, reinhilde ; Cassiman, Bruno.
    In: CEPR Discussion Papers.
    RePEc:cpr:ceprdp:3284.

    Full description at Econpapers || Download paper

47. External technology sources: Embodied or disembodied technology acquisition. (2000). veugelers, reinhilde ; Cassiman, Bruno.
    In: Economics Working Papers.
    RePEc:upf:upfgen:444.

    Full description at Econpapers || Download paper

48. Stable Coalition Structures with Open Membership and Asymmetric Firms. (2000). Belleflamme, Paul.
    In: Games and Economic Behavior.
    RePEc:eee:gamebe:v:30:y:2000:i:1:p:1-21.

    Full description at Econpapers || Download paper

49. Technological Opportunities, Absorptive Capacities, and Innovation. (2000). Becker, Wolfgang ; Peters, Jurgen.
    In: Discussion Paper Series.
    RePEc:aug:augsbe:0195.

    Full description at Econpapers || Download paper

50. Make and buy in innovation strategies: evidence from Belgian manufacturing firms. (1999). veugelers, reinhilde ; Cassiman, Bruno.
    In: Research Policy.
    RePEc:eee:respol:v:28:y:1999:i:1:p:63-80.

    Full description at Econpapers || Download paper

51. Learning by knowing through social capital : a missling link to research capability. (1998). Roberts, Edward Baer., ; International Center for Research on the Managemen, .
    In: Working papers.
    RePEc:mit:sloanp:2706.

    Full description at Econpapers || Download paper

52. The effects of social capital on technological performance of the firm : a a longitudinal analysis. (1998). Roberts, Edward Baer., ; International Center for Research on the Managemen, .
    In: Working papers.
    RePEc:mit:sloanp:2705.

    Full description at Econpapers || Download paper

53. The Evolution of Knowledge and the Dynamics of an Industry Network. (1997). Riccaboni, Massimo ; Pammolli, Fabio ; Turchetti, Giuseppe ; Bonaccorsi, Andrea.
    In: Journal of Management & Governance.
    RePEc:kap:jmgtgv:v:1:y:1997:i:2:p:147-175.

    Full description at Econpapers || Download paper

54. Present at the biotechnological revolution: transformation of technological identity for a large incumbent pharmaceutical firm. (1997). Zucker, Lynne ; Darby, Michael.
    In: Research Policy.
    RePEc:eee:respol:v:26:y:1997:i:4-5:p:429-446.

    Full description at Econpapers || Download paper

55. The role of institution-building in US industrial modernization programs. (1996). Kelley, Maryellen ; Arora, Ashish.
    In: Research Policy.
    RePEc:eee:respol:v:25:y:1996:i:2:p:265-279.

    Full description at Econpapers || Download paper

56. Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry. (1993). Henderson, Rebecca ; Cockburn, Iain.
    In: NBER Working Papers.
    RePEc:nbr:nberwo:4466.

    Full description at Econpapers || Download paper

57. Too much cocited documents. This list is not complete

Report date: 2025-09-29 23:02:17 || Missing content? Let us know